Abbott Laboratories Current Ratio 2012-2025 | ABT
Current and historical current ratio for Abbott Laboratories (ABT) from 2012 to 2025. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Abbott Laboratories current ratio for the three months ending December 31, 2025 was 0.00.
| Abbott Laboratories Current Ratio Historical Data | |||
|---|---|---|---|
| Date | Current Assets | Current Liabilities | Current Ratio |
| 2025-12-31 | $0.00B | 0.00 | |
| 2025-09-30 | $24.84B | $14.58B | 1.70 |
| 2025-06-30 | $24.47B | $13.44B | 1.82 |
| 2025-03-31 | $23.15B | $13.00B | 1.78 |
| 2024-12-31 | $23.66B | $14.16B | 1.67 |
| 2024-09-30 | $23.80B | $14.90B | 1.60 |
| 2024-06-30 | $23.12B | $13.76B | 1.68 |
| 2024-03-31 | $22.38B | $14.02B | 1.60 |
| 2023-12-31 | $22.67B | $13.84B | 1.64 |
| 2023-09-30 | $22.66B | $13.04B | 1.74 |
| 2023-06-30 | $23.51B | $14.35B | 1.64 |
| 2023-03-31 | $24.38B | $14.53B | 1.68 |
| 2022-12-31 | $25.22B | $15.49B | 1.63 |
| 2022-09-30 | $24.85B | $13.37B | 1.86 |
| 2022-06-30 | $24.96B | $12.39B | 2.01 |
| 2022-03-31 | $23.43B | $12.65B | 1.85 |
| 2021-12-31 | $24.24B | $13.11B | 1.85 |
| 2021-09-30 | $23.49B | $12.87B | 1.83 |
| 2021-06-30 | $22.63B | $12.61B | 1.79 |
| 2021-03-31 | $21.82B | $12.46B | 1.75 |
| 2020-12-31 | $20.44B | $11.91B | 1.72 |
| 2020-09-30 | $17.39B | $10.26B | 1.70 |
| 2020-06-30 | $17.22B | $10.96B | 1.57 |
| 2020-03-31 | $15.50B | $10.81B | 1.43 |
| 2019-12-31 | $15.67B | $10.86B | 1.44 |
| 2019-09-30 | $16.12B | $10.49B | 1.54 |
| 2019-06-30 | $15.20B | $9.06B | 1.68 |
| 2019-03-31 | $14.41B | $9.11B | 1.58 |
| 2018-12-31 | $14.63B | $9.01B | 1.62 |
| 2018-09-30 | $18.20B | $12.78B | 1.42 |
| 2018-06-30 | $14.12B | $8.95B | 1.58 |
| 2018-03-31 | $14.96B | $9.01B | 1.66 |
| 2017-12-31 | $20.15B | $8.91B | 2.26 |
| 2017-09-30 | $21.38B | $7.94B | 2.69 |
| 2017-06-30 | $19.98B | $6.80B | 2.94 |
| 2017-03-31 | $19.33B | $6.65B | 2.91 |
| 2016-12-31 | $26.78B | $6.66B | 4.02 |
| 2016-09-30 | $12.98B | $8.32B | 1.56 |
| 2016-06-30 | $12.99B | $8.67B | 1.50 |
| 2016-03-31 | $12.41B | $8.39B | 1.48 |
| 2015-12-31 | $14.16B | $9.19B | 1.54 |
| 2015-09-30 | $15.89B | $8.76B | 1.82 |
| 2015-06-30 | $21.13B | $9.19B | 2.30 |
| 2015-03-31 | $19.99B | $9.21B | 2.17 |
| 2014-12-31 | $13.56B | $10.47B | 1.30 |
| 2014-09-30 | $16.46B | $10.82B | 1.52 |
| 2014-06-30 | $18.26B | $9.85B | 1.85 |
| 2014-03-31 | $17.93B | $10.19B | 1.76 |
| 2013-12-31 | $19.25B | $9.51B | 2.03 |
| 2013-09-30 | $19.75B | $11.33B | 1.74 |
| 2013-06-30 | $19.83B | $10.92B | 1.82 |
| 2013-03-31 | $19.10B | $10.41B | 1.84 |
| 2012-12-31 | $31.32B | $13.28B | 2.36 |
| 2012-09-30 | $27.26B | $16.29B | 1.67 |
| 2012-06-30 | $26.26B | $17.12B | 1.53 |
| 2012-03-31 | $25.60B | $16.79B | 1.53 |
| 2011-12-31 | $23.77B | $15.48B | 1.54 |
| 2011-09-30 | $23.09B | $15.41B | 1.50 |
| 2011-06-30 | $24.13B | $15.84B | 1.52 |
| 2011-03-31 | $23.65B | $17.23B | 1.37 |
| 2010-12-31 | $22.32B | $17.26B | 1.29 |
| 2010-09-30 | $19.45B | $15.58B | 1.25 |
| 2010-06-30 | $19.92B | $14.69B | 1.36 |
| 2010-03-31 | $17.69B | $15.18B | 1.17 |
| 2009-12-31 | $23.31B | $13.05B | 1.79 |
| 2009-09-30 | $21.42B | $12.53B | 1.71 |
| 2009-06-30 | $19.63B | $12.04B | 1.63 |
| 2009-03-31 | $18.01B | $11.77B | 1.53 |
| 2008-12-31 | $17.04B | $11.59B | 1.47 |
| 2008-09-30 | $15.23B | $9.56B | 1.59 |
| 2008-06-30 | $16.96B | $12.02B | 1.41 |
| 2008-03-31 | $15.11B | $10.77B | 1.40 |
| 2007-12-31 | $14.04B | $9.10B | 1.54 |
| 2007-09-30 | $12.84B | $12.28B | 1.05 |
| 2007-06-30 | $12.34B | $12.01B | 1.03 |
| 2007-03-31 | $11.50B | $12.31B | 0.94 |
| 2006-12-31 | $11.28B | $11.95B | 0.94 |
| 2006-09-30 | $10.07B | $7.43B | 1.36 |
| 2006-06-30 | $9.90B | $7.69B | 1.29 |
| 2006-03-31 | $10.61B | $7.16B | 1.48 |
| 2005-12-31 | $11.39B | $7.42B | 1.54 |
| 2005-09-30 | $10.99B | $8.76B | 1.26 |
| 2005-06-30 | $9.66B | $6.08B | 1.59 |
| 2005-03-31 | $10.35B | $7.37B | 1.41 |
| 2004-12-31 | $10.73B | $6.83B | 1.57 |
| 2004-09-30 | $10.22B | $7.30B | 1.40 |
| 2004-06-30 | $10.50B | $7.62B | 1.38 |
| 2004-03-31 | $10.94B | $6.95B | 1.57 |
| 2003-12-31 | $9.61B | $6.96B | 1.38 |
| 2003-09-30 | $10.26B | $8.04B | 1.28 |
| 2003-06-30 | $9.72B | $7.33B | 1.33 |
| 2003-03-31 | $9.43B | $6.94B | 1.36 |
| 2002-12-31 | $8.46B | $6.34B | 1.34 |
| 2002-09-30 | $8.48B | $6.72B | 1.26 |
| 2002-06-30 | $8.01B | $6.87B | 1.17 |
| 2002-03-31 | $8.08B | $6.95B | 1.16 |
| 2001-12-31 | $8.42B | $7.93B | 1.06 |
| 2001-09-30 | $8.17B | $7.78B | 1.05 |
| 2001-06-30 | $7.96B | $7.41B | 1.08 |
| 2001-03-31 | $8.19B | $10.89B | 0.75 |
| 2000-12-31 | $7.38B | $4.30B | 1.72 |
| 2000-09-30 | $6.97B | $4.28B | 1.63 |
| 2000-06-30 | $6.90B | $4.19B | 1.65 |
| 2000-03-31 | $6.73B | $4.50B | 1.50 |
| 1999-12-31 | $6.42B | $4.52B | 1.42 |
| 1999-09-30 | $5.88B | $4.33B | 1.36 |
| 1999-06-30 | $5.55B | $4.17B | 1.33 |
| 1999-03-31 | $5.77B | $4.71B | 1.23 |
| 1998-12-31 | $5.55B | $4.96B | 1.12 |
| 1998-09-30 | $5.07B | $4.67B | 1.09 |
| 1998-06-30 | $5.18B | $5.00B | 1.04 |
| 1998-03-31 | $5.18B | $4.73B | 1.10 |
| 1997-12-31 | $5.04B | $5.03B | 1.00 |
| 1997-09-30 | $4.65B | $4.72B | 0.99 |
| 1997-06-30 | $4.59B | $4.51B | 1.02 |
| 1997-03-31 | $4.63B | $4.38B | 1.06 |
| 1996-12-31 | $4.48B | $4.34B | 1.03 |
| 1996-09-30 | $4.27B | $4.29B | 1.00 |
| 1996-06-30 | $4.33B | $4.53B | 0.96 |
| 1996-03-31 | $4.11B | $3.49B | 1.18 |
| 1995-12-31 | $4.23B | $3.79B | 1.12 |
| 1995-09-30 | $4.08B | $3.57B | 1.14 |
| 1995-06-30 | $4.04B | $3.54B | 1.14 |
| 1995-03-31 | $3.89B | $3.59B | 1.08 |
| 1994-12-31 | $3.88B | $3.48B | 1.12 |
| 1994-09-30 | $3.86B | $3.41B | 1.13 |
| 1994-06-30 | $3.72B | $3.27B | 1.14 |
| 1994-03-31 | $3.52B | $3.05B | 1.15 |
| 1993-12-31 | $3.59B | $3.10B | 1.16 |
| 1993-09-30 | $3.55B | $3.12B | 1.14 |
| 1993-06-30 | $3.45B | $3.06B | 1.13 |
| 1993-03-31 | $3.35B | $3.00B | 1.12 |
| 1992-12-31 | $3.23B | $2.78B | 1.16 |
| 1992-09-30 | $3.30B | $2.68B | 1.23 |
| 1992-06-30 | $3.03B | $2.32B | 1.31 |
| 1992-03-31 | $2.93B | $2.25B | 1.30 |
| 1991-12-31 | $2.89B | $2.23B | 1.30 |
| 1991-09-30 | $2.72B | $2.06B | 1.32 |
| 1991-06-30 | $2.73B | $2.07B | 1.32 |
| 1991-03-31 | $2.68B | $2.04B | 1.31 |
| 1990-12-31 | $2.46B | $2.00B | 1.23 |
| 1990-09-30 | $2.69B | $2.18B | 1.24 |
| 1990-06-30 | $2.50B | $1.90B | 1.32 |
| 1990-03-31 | $2.32B | $1.66B | 1.40 |
| 1989-12-31 | $2.10B | $1.38B | 1.52 |
| 1989-09-30 | $2.37B | $1.64B | 1.45 |
| 1989-06-30 | $2.27B | $1.43B | 1.58 |
| 1989-03-31 | $2.20B | $1.28B | 1.71 |
| 1988-12-31 | $2.35B | $1.44B | 1.63 |
| 1988-09-30 | $2.20B | $1.42B | 1.55 |
| 1988-06-30 | $2.22B | $1.44B | 1.54 |
| 1988-03-31 | $2.12B | $1.45B | 1.46 |
| 1987-12-31 | $2.16B | $1.49B | 1.45 |
| 1987-09-30 | $2.01B | $1.37B | 1.46 |
| 1987-06-30 | $1.99B | $1.37B | 1.46 |
| 1987-03-31 | $1.97B | $1.32B | 1.49 |
| 1986-12-31 | $1.89B | $1.30B | 1.45 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $174.688B | $44.328B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $129.889B | 24.88 |
| Medtronic (MDT) | Ireland | $111.968B | 15.57 |
| EssilorLuxottica (ESLOY) | France | $107.724B | 0.00 |
| Boston Scientific (BSX) | United States | $91.831B | 20.26 |
| Medline (MDLN) | United States | $59.904B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $45.712B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $33.391B | 15.98 |
| ResMed (RMD) | United States | $33.341B | 22.26 |
| Agilent Technologies (A) | United States | $32.516B | 20.44 |
| Koninklijke Philips (PHG) | Netherlands | $27.260B | 16.18 |
| Terumo (TRUMY) | Japan | $19.854B | 23.21 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.025B | 11.36 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $14.227B | 0.00 |
| Insulet (PODD) | United States | $13.640B | 39.54 |
| Baxter (BAX) | United States | $8.854B | 7.56 |
| Sunny Optical Technology (SNPTF) | China | $8.381B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.537B | 28.15 |
| Demant (WILYY) | Denmark | $6.395B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.247B | 15.90 |
| Envista Holdings (NVST) | United States | $4.301B | 21.99 |
| BillionToOne (BLLN) | United States | $3.729B | 0.00 |
| DiaSorin S.p.A (DSRLF) | Italy | $3.666B | 0.00 |
| ICU Medical (ICUI) | United States | $3.141B | 20.47 |
| Prestige Consumer Healthcare (PBH) | United States | $2.676B | 12.62 |
| Haemonetics (HAE) | United States | $2.664B | 11.65 |
| LeMaitre Vascular (LMAT) | United States | $2.611B | 48.16 |
| Phibro Animal Health (PAHC) | United States | $2.347B | 20.67 |
| GN Store Nord (GNNDY) | Denmark | $2.270B | 21.90 |
| Neogen (NEOG) | United States | $2.050B | 44.86 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $2.028B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $1.794B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.654B | 32.89 |
| Curaleaf Holdings (CURLF) | Canada | $1.584B | 0.00 |
| Perrigo (PRGO) | Ireland | $1.495B | 3.96 |
| AtriCure (ATRC) | United States | $1.429B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.386B | 15.91 |
| Kestra Medical Technologies (KMTS) | United States | $1.043B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.953B | 164.50 |
| QuidelOrtho (QDEL) | United States | $0.943B | 6.53 |
| Lumexa Imaging Holdings (LMRI) | United States | $0.896B | 0.00 |
| InMode (INMD) | Israel | $0.857B | 9.40 |
| Omeros (OMER) | United States | $0.827B | 6.49 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.789B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.766B | 0.00 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Brainsway (BWAY) | Israel | $0.546B | 55.68 |
| Valneva SE (VALN) | France | $0.532B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.468B | 11.18 |
| Cresco Labs (CRLBF) | United States | $0.458B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.424B | 0.00 |
| Verano Holdings (VRNO) | United States | $0.415B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.367B | 25.70 |
| SNDL (SNDL) | Canada | $0.366B | 0.00 |
| Cerus (CERS) | United States | $0.363B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.311B | 126.00 |
| Evolus (EOLS) | United States | $0.278B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.259B | 0.00 |
| MacroGenics (MGNX) | United States | $0.229B | 0.00 |
| Owens & Minor (OMI) | United States | $0.217B | 2.17 |
| Accendra Health (ACH) | United States | $0.215B | 2.96 |
| Utah Medical Products (UTMD) | United States | $0.210B | 18.94 |
| High Tide (HITI) | Canada | $0.205B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.205B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.194B | 57.17 |
| TerrAscend (TSNDF) | Canada | $0.193B | 0.00 |
| Organigram Global (OGI) | Canada | $0.191B | 0.00 |
| Apyx Medical (APYX) | United States | $0.166B | 0.00 |
| Quanterix (QTRX) | United States | $0.158B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.157B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.152B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.145B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.143B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.133B | 0.00 |
| Fonar (FONR) | United States | $0.115B | 16.53 |
| Jushi Holdings (JUSHF) | United States | $0.101B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.090B | 11.73 |
| Exagen (XGN) | United States | $0.073B | 0.00 |
| Sharps Technology (STSS) | United States | $0.065B | 0.00 |
| ImmuCell (ICCC) | United States | $0.064B | 0.00 |
| Biote (BTMD) | United States | $0.063B | 3.46 |
| INLIF (INLF) | China | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| Veru (VERU) | United States | $0.038B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.036B | 0.00 |
| Nephros (NEPH) | United States | $0.032B | 26.91 |
| United-Guardian (UG) | United States | $0.030B | 14.23 |
| Bonk (BNKK) | United States | $0.021B | 0.00 |
| Jin Medical (ZJYL) | China | $0.018B | 0.00 |
| Modular Medical (MODD) | United States | $0.013B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Zynex (ZYXI) | United States | $0.004B | 0.00 |
| Functional Brands (MEHA) | United States | $0.003B | 0.00 |
| Agape ATP (ATPC) | $0.003B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.002B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.002B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |